Home / Healthcare / KemPharm, Inc. - Product Pipeline Review - 2015

KemPharm, Inc. - Product Pipeline Review - 2015

Published: Aug 2015 | No Of Pages: 33 | Published By: Global Markets Direct

KemPharm, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'KemPharm, Inc. - Product Pipeline Review - 2015', provides an overview of the KemPharm, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of KemPharm, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of KemPharm, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of KemPharm, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the KemPharm, Inc.'s pipeline products

Reasons to buy

- Evaluate KemPharm, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of KemPharm, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the KemPharm, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of KemPharm, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of KemPharm, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of KemPharm, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
KemPharm, Inc. Snapshot 5
KemPharm, Inc. Overview 5
Key Information 5
Key Facts 5
KemPharm, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
KemPharm, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
KemPharm, Inc. - Pipeline Products Glance 11
KemPharm, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
KemPharm, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
KemPharm, Inc. - Drug Profiles 13
(benzhydrocodone hydrochloride + acetaminophen) IR 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
KP-303 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
KP-415 CR 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
KP-511 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
KP-511 ER 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
KP-606 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
KP-606 ER 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
KemPharm, Inc. - Pipeline Analysis 22
KemPharm, Inc. - Pipeline Products by Target 22
KemPharm, Inc. - Pipeline Products by Route of Administration 23
KemPharm, Inc. - Pipeline Products by Molecule Type 24
KemPharm, Inc. - Pipeline Products by Mechanism of Action 25
KemPharm, Inc. - Recent Pipeline Updates 26
KemPharm, Inc. - Dormant Projects 30
KemPharm, Inc. - Locations And Subsidiaries 31
Head Office 31
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 32
Disclaimer 33

KemPharm, Inc., Key Information 5
KemPharm, Inc., Key Facts 5
KemPharm, Inc. - Pipeline by Indication, 2015 7
KemPharm, Inc. - Pipeline by Stage of Development, 2015 8
KemPharm, Inc. - Monotherapy Products in Pipeline, 2015 9
KemPharm, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
KemPharm, Inc. - Phase I, 2015 11
KemPharm, Inc. - Preclinical, 2015 12
KemPharm, Inc. - Pipeline by Target, 2015 22
KemPharm, Inc. - Pipeline by Route of Administration, 2015 23
KemPharm, Inc. - Pipeline by Molecule Type, 2015 24
KemPharm, Inc. - Pipeline Products by Mechanism of Action, 2015 25
KemPharm, Inc. - Recent Pipeline Updates, 2015 26
KemPharm, Inc. - Dormant Developmental Projects,2015 30

KemPharm, Inc. - Pipeline by Top 10 Indication, 2015 7
KemPharm, Inc. - Pipeline by Stage of Development, 2015 8
KemPharm, Inc. - Pipeline by Top 10 Target, 2015 22
KemPharm, Inc. - Pipeline by Top 10 Route of Administration, 2015 23
KemPharm, Inc. - Pipeline by Top 10 Molecule Type, 2015 24
KemPharm, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 25

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +